Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00215150
Status:
COMPLETED
Last Update Posted:
2014-10-31
First Post:
2005-09-20
Brief Title:
Geodon for the Treatment of Refractory Social Anxiety Disorder
Sponsor:
Duke University
Organization:
Duke University
Study Overview
Official Title:
Ziprasidone for the Treatment of Refractory Social Anxiety Disorder
Status:
COMPLETED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SAD
Brief Summary:
The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder SAD who did not remit on sertraline treatment alone
Detailed Description:
This is a two-phase study consisting of 8 weeks of open label treatment with sertraline 50-200 mgday in patients with SAD and in those who fail to demonstrate symptom remission on sertraline alone 8 weeks of randomized double-blind placebo-controlled augmentation with ziprasidone
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 6479 | OTHER | Duke legacy protocol number | None |